Stable Knockdown of Adenosine Kinase by Lentiviral Anti-ADK miR-shRNAs in Whartonâ��s Jelly Stem Cells by Estiri, H. et al.
1Cell J, Vol 20, No 1, Apr-Jun (Spring) 2018
Original Article
Stable Knockdown of Adenosine Kinase by Lentiviral Anti-ADK
 miR-shRNAs in Wharton’s Jelly Stem Cells
 Hajar Estiri, Ph.D.1, 2,  Ali Fallah, Ph.D.3, 2, Masoud Soleimani, Ph.D.4, Abbas Aliaghaei, Ph.D.5, Fariba 
Karimzadeh, Ph.D.6, Shahnaz Babaei Abraki, M.Sc.7, Mohammad Hossein Ghahremani, Ph.D.1, 8*
1. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Iranian Institute of Cell and Gene therapy, Tehran, Iran 
3. Bioviva Science USA, Seattle, USA
4. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5. Neuroscience Lab, Department of Anatomy and Cell Biology, School of Medicine, Shahid Beheshti University of Medical
 Sciences, Tehran, Iran
6. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
7. Shefa Neuroscience Research Center, Khatam-al-Anbia Hospital, Tehran, Iran
8. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Address: P.O. BOX: 14155/6451, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran 
University of Medical Sciences, Tehran, Iran
Email: mhghahremani@tums.ac.ir
 
Received: 27/Nov/2016, Accepted: 9/Feb/2017
Abstract
Objective: In this study, we describe an efficient approach for stable knockdown of adenosine kinase (ADK) using lentiviral 
system, in an astrocytoma cell line and in human Wharton’s jelly mesenchymal stem cells (hWJMSCs). These sources of stem 
cells besides having multilineage differentiation potential and immunomodulatory activities, are easily available in unlimited 
numbers, do not raise ethical concerns and are attractive for gene manipulation and cell-based gene therapy.
Materials and Methods: In this experimental study, we targeted adenosine kinase mRNA at 3' and performed coding 
sequences using eight miR-based expressing cassettes of anti-ADK short hairpin RNA (shRNAs). First, these cassettes with 
scrambled control sequences were cloned into expressing lentiviral pGIPZ vector. Quantitative real time-polymerase chain 
reaction (qRT-PCR) was used to screen multi-cassettes anti-ADK miR-shRNAs in stably transduced U-251 MG cell line and 
measuring ADK gene expression at mRNA level. Extracted WJMSCs were characterized using flow cytometry for expressing 
mesenchymal specific marker (CD44+) and lack of expression of hematopoietic lineage marker (CD45-). Then, the lentiviral 
vector that expressed the most efficient anti-ADK miR-shRNA, was employed to stably transduce WJMSCs.       
Results: Transfection of anti-ADK miR-shRNAs in HEK293T cells using CaPO4 method showed high efficiency. We 
successfully transduced U-251 cell line by recombinant lentiviruses and screened eight cassettes of anti-ADK miR-
shRNAs in stably transduced U-251 MG cell line by qRT-PCR. RNAi-mediated down-regulation of ADK by lentiviral 
system indicated up to 95% down-regulation of ADK. Following lentiviral transduction of WJMSCs with anti-ADK miR-
shRNA expression cassette, we also implicated, down-regulation of ADK up to 95% by qRT-PCR and confirmed it by 
western blot analysis at the protein level.                   
Conclusion: Our findings indicate efficient usage of shRNA cassette for ADK knockdown. Engineered WJMSCs with 
genome editing methods like CRISPR/cas9 or more safe viral systems such as adeno-associated vectors (AAV) might 
be an attractive source in cell-based gene therapy and may have therapeutic potential for epilepsy.          
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Introduction
Previous molecular studies indicated that up-regulation of 
adenosine kinase (ADK), a key enzyme in the metabolism 
of adenosine, is one of the most important processes 
involved in astrogliosis (1, 2). RNA interference (RNAi) 
or post-transcriptional gene silencing (PTGS) is an 
interesting molecular tool for gene knockdown. Knock 
down of ADK increases intracellular adenine and results 
in extracellular adenosine augmentation. Adenosine has 
known protective effects on the central nervous system (3, 
4). ADK gene could be targeted by RNAi in human cells which 
is an effective way to produce adenosine-releasing cells (5, 
6). Adenosine augmentation exhibits a paracrine therapeutic 
effect and has potential for therapeutic applications in 
neurological diseases like refractory epilepsy (7).
Among children, the highest incidence of epilepsy is seen at 
ages less than five years old. Therefore, finding a new source 
of cells with therapeutic applications is highly required (8). 
Wharton’s jelly stem cells (WJMSCs) are an alternative 
for bone marrow mesenchymal stem cell (BMSCs). 
They are multipotent cells which are easily isolated in 
unlimited numbers with long-term ex vivo proliferation and 
immunomodulatory properties (9). WJMSCs are obtained 
from discarded human umbilical cord, with no ethical concern 
(10). These cells express specific MSCs markers like CD44 
and are negative for CD45 hematopoietic lineage marker (11, 
12). Being easily accessible, makes WJMSCs an alternative 
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and attractable source for cell-based gene therapy. 
In the present study, we used anti-ADK microRNA (miR) 
in a shRNA lentiviral systems (miR-shRNA) for ex vivo gene 
therapy in U-251 MG cell line. We screened eight cassettes 
of miR-shRNAs that target human ADK gene. In order to 
screen and select the most efficient anti-ADK miR-shRNA, 
astrocytoma cell line was employed. Human U-251 MG 
cell line highly expresses ADK gene. Pseudo lentiviruses of 
eight anti-ADK miR-shRNAs were used for transducing of 
astrocytoma cell lines. The most efficient anti-ADK miR-
shRNA for knockdown of ADK was selected by quantitative 
real time-polymerase chain reaction (qRT-PCR) analysis 
of established cells. Furthermore, human WJMSCs were 
isolated and cultured after characterizing with flow cytometry 
for specific mesenchymal markers. Knockdown of ADK gene 
in WJMSCs was confirmed by western blot analysis as well 
as qRT-PCR after transduction using the most efficient anti-
ADK miR-shRNA lentiviral vector.
Materials and Methods 
In this experimental study, human U-251 MG cell line 
(Sigma-Aldrich, USA) was cultured with Dulbecco’s 
Modified Eagle’s Medium (DMEM, Gibco-BRL, Japan) 
and 10% fetal bovine serum (FBS, Gibco, USA). This cell 
line highly expresses ADK gene. The third passage of these 
cells was used for screening the anti-ADK miR-shRNAs to 
knockdown ADK gene. All the experiments including animal 
works were approved by TUMS Ethics committee No. 93-
01-87-25045-109011 and were  performed based on the 
committee guideline.
Lentiviral constructs for the expression of anti-ADK 
miR-shRNAs
The eight different pre-miRNA sequences and a randomized 
scrambled control (SC) sequence were purchased (GE 
Healthcare). All miR-shRNA cassettes were cloned into 
the pGIPZ lentiviral vector, which contained a TurboGFP 
green fluorescence protein (tGFP) as a reporter gene, internal 
ribosome entry site (IRES) and a puromycin resistance gene; 
thus, it allowed co-expression of the respective miR-shRNA 
with tGFP and selection of stably transduced cells with 
puromycin. Expression of tGFP, puromycin and miR-shRNAs 
were under Cytomegalovirus (CMV) constant promoter. All 
genes were expressed as a single mRNA. At first, mRNA was 
processed in nuclear for producing premature miR-shRNA 
and bicistronic GFP-puromycin mRNA. pGIPZ lentiviral 
expression vector harbored internal long terminal repeats 
(LTRs)  zeocin selection marker for selection of correct intact 
vector during bacterial propagation. 
Production of recombinant pseudo lentiviruses
Recombinant lentiviruses were produced according to the 
Prof. Trono lab protocol with some modifications (13, 14). 
Briefly for all 8 miR-shRNAs and the positive control vector, 
1×106 HEK 293T cells (Invitrogen, USA) were cultured 
in a 10-cm2 plate in DMEM medium supplemented with 
10% FBS one day prior to transfection. Two hours before 
transfection, the medium was replaced with fresh medium. 
The transfection mixture contained 21 μg of pGIPZ-miR-
sh/SC, 15 μg of pCMV-dR8.2, 10.5 μg of pMD2, 33 μl of 
TE 1X, 105 μl of 2.5 M CaCl
2
, and 1064 μl of 2X HEPES-
buffered saline (HeBS) finally reaching a volume of 2100 μl 
using buffered water. 
All the components were mixed, and HeBS 2X was added 
when the solution was being vortexed vigorously. The 
final volume of transfection mixture used for each 10-cm2 
plate, was 2100 μl. HEK 293T cells were incubated with 
transfection solution in 37˚C for 14 hours. The transfection 
medium was replaced with fresh medium 14 hours after 
transfection and cells were assayed for GFP expression using 
a fluorescent microscope (LaboMed, USA). GFP expression 
indicated transfection efficiency. To estimate the transfection 
rate, five fields were randomly observed under the fluorescent 
microscope. Supernatant of cells containing recombinant 
viruses was collected at three time points (24, 48 and 72 hours 
after transfection) after 14 hours post-transfection. Next, 
collected supernatants were centrifuged at 180 g and filtered 
through a 0.25 μm filter before concentration and titration. 
For concentration of the supernatants, we used PEG 6000 and 
9000 g centrifuge. The lentiviral titers from the 9 different 
miR-shRNA constructs due to tGFP gene in our vectors were 
determined using flow cytometry method. The determination 
of the lentiviral titer allowed us to estimate the multiplicity of 
infection (MOI) and thus to reduce the infectious activity of 
the viral stocks.
Determination of lentivirus titration
Since the stocks of vector carry GFP transgene that can be 
easily monitored by flow cytometer, we used this method for 
titration of lentivectors. We used Prof. Trono lab protocol for 
lentivirus titration (15). For this purpose, 293T cells were 
cultured in DMEM medium supplemented with 10% FBS in a 
12-well plate with 1×105 cells in each well. Then, the medium 
was removed and cells were transduced in 500 μl of fresh 
DMEM with serial dilutions of the vector that corresponded 
to the final amount of 1, 10−1, 10−2, 10−3, 10−4 and 10−5 μl of the 
vector. After 24 hours, the medium was removed and one ml 
of fresh medium was added to each well. Then, 72 hours after 
transduction, cells were processed for Fluorescence Activated 
Cell Sorting (FACS) analysis. The following formula was 
used for calculating titer by flow cytometry:
"Titer HEK 293T transducing U/ml=[Number of target cells 
(counted on day 1)×(% of GFP-positive cells/100)]/volume 
of supernatant (ml)"
Ideally, the cells should present 2-20% GFP+ to confirm 
that cells that received multiple copies of the virus, were 
not counted. The flow cytometer apparatus did not have 
enough sensitivity for determination of GFP+ <1% .  
Genetic engineering of U-251 MG cell line
After three passages, U-251 MG was cultured in six-well 
cell culture plates at a density of 2×105 cell /well /2 ml. Before 
adding fresh recombinant viruses, U-251 MG cell line was 
washed with PBS. Recombinant viruses in culture medium 
with an MOI of 5 were used for transduction of cells in each 
well. To increase the rate of transduction, the spinfection 
method was used. After infection, the plates were incubated at 
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37˚C and the medium was changed 24 hours later. Transduced 
cells were assayed for GFP expression with a fluorescent 
microscope (LaboMed, USA), 72 hours after transduction. 
GFP expression indirectly indicated the expression of miR-
shRNA and transduction efficiency. To select stably transduced 
cells, from day 4, the medium was replaced with fresh medium 
containing 2 µg/ml puromycin for 5-7 days.
Quantitative analysis of ADK knockdown by real-time 
analysis in U-251 MG cells
A QuantiFast SYBR Green RT-PCR Kit (Qiagen, USA) 
was employed to determine and monitor ADK expression after 
knockdown of this gene by recombinant lentiviral constructs 
that express anti-ADK miR-shRNAs. After puromycin 
selection, 2×106 cells from stable U-251 MG cell line was 
used for RNA extraction and cDNA synthesis (Qiagen kit, 
USA). According to the manufacturer protocols, cDNA was 
used for standard real-time PCR. Specific primer pairs were 
used for ADK and TBP (TATA Sequence-Binding Protein). 
The expression of ADK mRNA was evaluated in the lentiviral-
engineered U-251 MG cells. For improving the reliability of 
relative RT-PCR, TBP was used as a reference gene.
Isolation and expansion of human Wharton’s jelly 
mesenchymal stem cells
Human Wharton’s jelly tissues were obtained from 
newborn umbilical cord in accordance with bioethics 
agreement following obtaining the consent from its mother 
at Taleghani Hospital, Tehran, Iran. Mucoid connective tissue 
or Wharton’s jelly were separated from blood vessels (two 
arteries and one vein of the umbilical cord) then, washed 
twice with PBS containing penicillin, streptomycin and 
amphotericin. The cord was rinsed with PBS and isolated 
from amniotic membrane. After separation of the matrix 
from cord vessels, the jelly matrix was cut into small pieces 
and transferred into culture dishes supplemented with  DME/
F12 medium, 10% FBS and antibiotics. Two weeks later, 
the tissues were discarded and the isolated growing cells 
(WJMSCs) were fed with the same medium. The cells were 
grown to 60% confluence and passaged by trypsinization. 
The third passage of WJMSCs was used for characterization.
Flow cytometry 
A number of 1×105 cultured WJMSCs were washed, fixed 
and incubated for 15 minutes at 4˚C  with a 1:9 dilution of 
normal goat serum in phosphate buffered saline (PBS, Sigma-
Aldrich, USA). Then, cells were incubated for 1 hour with 
FITC-conjugated antibodies (CD44 and CD45) for labelling. 
Cells washed with 2% FBS in PBS were used for analyzing 
with FACSCalibur apparatus (Becton Dickenson, USA). The 
control population was stained with isotype-matched antibodies 
(FITC-conjugated and PE-conjugated mouse IgG monoclonal 
isotype standards) and confirmed by positive fluorescence of 
the limbal samples. For each sample, at least 1×104 events were 
recorded and analyzed by WinMDI software (USA).
Quantitative analysis of ADK knockdown by selected 
anti-ADK miR-shRNA in Wharton’s jelly mesenchymal 
stem cells
A QuantiFast SYBR Green RT-PCR Kit (Qiagen, 
Germany) was employed to monitor knockdown of ADK after 
transduction of WJMSCs by the most efficient recombinant 
lentiviral construct that expressed anti-ADK miR-shRNA. 
After puromycin selection with 2 µg/ml for 5-7 days, 1×106 
cells from WJMSCs were used for RNA extraction and cDNA 
synthesis (Qiagen, Gemany). In the second step, cDNA was 
used for standard real-time PCR. Specific primer pairs were 
used for ADK and TBP. The expression of ADK mRNA was 
evaluated in the lentiviral-engineered WJMSCs cells. 
Preparation of total protein extracts
Stable transduced umbilical cord mesenchymal stem cells 
(WJMSCs) were lysed using ReadyPrep™ mammalian 
cell lysis reagent (Bio-Rad) comprising complete protease 
inhibitor cocktail. Cellular proteins were prepared according 
to manufacturer’s protein extraction protocol. The samples 
were stored at -80∘C until western blot analysis. The protein 
content of sample lysate was measured using Bradford’s 
method (16).
Western blot analysis
An equal amount of proteins was loaded on 12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene fluoride membranes. 
Blots were blocked using non-fat dry milk for 1 hour. After 
blocking, membranes were probed with ADK primary 
antibody (Santa Cruz, 1/1000). Then anti-rabbit IgG antibody 
conjugated with horseradish peroxidase (Santa Cruz, 1/8000) 
was used for 1 hour at room temperature. Subsequently, the 
blots were reprobed with a β-actin antibody (1:2000, Abcam, 
ab8227, USA). Then, the blots were treated with Electro 
Chemi Luminescence reagents (Amersham Biosciences, 
UK). For quantification of protein intensities, western blot 
bands were visualized on radiograph film and evaluated by 
Image J software. Human umbilical cord tissue was used in 
accordance with the Declarations of Tehran University of 
Medical Science and Stem Cell Research Center Committee 
after obtaining written informed consent from the mother.
Results
Transfection efficiency of lentiviral anti-ADK miR-
shRNAs vectors in packaging 293T cell line  
All of nine transfer vectors (eight anti-ADK miR-
shRNAs and scrambled control) with helper vectors 
(pCMV-dR8.2 and pMD2) were separately co-transfected 
into HEK293T cell line using CaCl
2
 protocol. The 
transfection efficiency, as evaluated based on GFP marker 
under the fluorescent microscope, was more than 90-95% 
for eight anti-ADK miR-shRNAs (Fig.1) and scrambled 
control.
Titration of lentivirus by FACS
The titer of viral particles was approximately 1.5-2×107 
U/ml. Serial dilutions of the vector that corresponded to 
the final amount of 10-3-10-4 μl of the vector, were used 
for calculating the titration because the GFP+ cells in other 
 Cell J, Vol 20, No 1, Apr-Jun (Spring) 2018 4
Stable Knockdown of ADK by Lentiviral
serial dilutions were more than 20% or under 1%.
Transduction of U-251 MG cell line  
As U-251 MG cell line highly expresses ADK gene, 
we chose it for screening anti-ADK miR-shRNAs 
(Fig.2). Nine recombinant pseudo lentiviruses (eight 
anti-ADK miR-shRNAs and scrambled control) 
were separately used for transduction of U-251 MG 
cell line. GFP reporter gene showed high efficiency 
of transduction and expression of anti-ADK miR-
shRNAs and scrambled pseudo lentiviruses in U-251 
MG cells (Fig.3). Selection of GFP+ cells, 72 hours 
after transduction, was done by using puromycin (2 
µg/ml) (Fig.4).
Fig.1: Transfection efficiency of lentiviral anti-ADK miR-shRNAs vectors in packaging 293T cell line. A-H. HEK 293T cells were transfected with anti-ADK miR-
shRNAs and I. Scrambled control with high efficiency (90-95%). The rate of GFP expression evaluated undera fluorescent, microscope confirmed the high 
efficiency of transfection and expression of anti-ADK miR-shRNAs. 
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Fig.3: Lentiviral Transduction efficiency in U-251 MG cell line. High rate of tGFP expression was seen under a fluorescent microscope 72 hours after 
transduction with anti-ADK miR-shRNAs lentiviral vectors. A-H. Transduction with sh1-sh8 and I. Transduction of cells with scrambled control. 
Fig.4: Antibiotic selection of transduced U-251 MG cell line. The stable cell line was produced by puromycin selection after 7 days. A, B. Depict the second 
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Screening of anti-ADK miR-shRNAs in U-251 MG 
cells by semi-quantitative real-time polymerase chain 
reaction
For selection of the most efficient anti-ADK miR-
shRNAs for ADK knockdown, quantitative real-time 
PCR was employed. Expression of ADK gene in each of 
target groups (U-251 MG cell line transduced with 8 anti-
ADK miR-shRNAs) was measured in proportion to control 
group (U-251 MG cell line transduced with scrambled 
control). For improving the reliability of relative RT-PCR, 
TBP was used as a reference gene. Analysis by quantitative 
real-time PCR was done by REST2009 software (Fig.5A). 
Data showed that anti-ADK miR-shRNAs, except for sh8, 
could knockdown ADK more than 60% and sh4 and sh7 
were the most efficient anti-ADK miR-shRNAs with 86 
and 95% knockdown of ADK, respectively (Fig.5B). 
Morphological characteristics and mesenchymal stem 
cell markers expression of human Wharton’s jelly cells 
Umbilical cord matrix tissue was cultured by an explant 
method. A few days later, WJMSCs migrated away from tissues. 
After two weeks, fibroblast-like cells appeared in culture dishes. 
The cells grew fast and rapidly covered the surface. Flow 
cytometric analyses indicated that the cultured WJMSCs do not 
express hematopoietic marker CD45; however, they expressed 
mesenchymal stem cell marker CD44 (Fig.6A).
Genetic engineering of WJMSCs by anti-ADK miR-sh7
Analysis of real-time data showed that Anti-ADK miR-
sh7 is the most efficient (up 95%) anti-ADK miR-shRNA 
for knockdown of this gene. For this reason, we used 
pseudo lentiviruses of this miR-shRNA for transduction 
of WJMSCs. The high efficiency of transduction was 
seen under the fluorescent microscope. After selection 
with puromycin (1.5 µg/ml) in the culture medium 
(Fig.6B), semi-quantitative real-time PCR was employed 
for measuring ADK expression at mRNA level. Data also 
showed knockdown of ADK gene in WJMSCs up to 95% 
as well as down-regulation in the U-251 MG cell line.
Confirm of ADK knockdown in WJMSCs by western 
blot analysis
After selection of transduced WJMSCs using anti-
ADK miR-sh7 lentiviral vector, cell lysates were used for 
performing western blot. Cell lysates from transduced 
WJMSCs with scrambled control viruses, cell lysates from 
WJMSCs and HepG2 as a control were also employed. 
To quantify and normalizing of ADK immunoreactivity, 
β-actin antibody were used. Analysis of data did not show 
any reduction of ADK in WJMSCs, WJMSCs-miR-shSC, 
and HepG2; however, down-regulation of ADK was 
observed after transducing cells with the human specific 
anti-ADK miR-sh7 (Fig.6C).
Fig.5: Screening of anti-ADK miR-shRNAs in U-251 MG cells by semiquantitative real-time polymerase chain reaction.  A. The expression of ADK mRNA was 
evaluated in the lentiviral-engineered U-251 MG cells by REST 2009 software. For improving the reliability of real-time polymerase chain reaction (RT-PCR), 
TBP was used as a reference gene and B. Percent of ADK knockdown obtained by anti-ADK miR-shRNAs. Data showed that anti-ADK miR-shRNAs (except 
for sh8) could knock down ADK more than 60% and sh4 and sh7 were the most efficient with 86 and 95% ADK knockdown, respectively.
A
B
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Fig.6:  Knock down of ADK in human Wharton’s jelly cells. A. Morphological characteristics and mesenchymal stem cell markers expression of human 
Wharton’s jelly cells. WJMSCs showed fibroblast-like phenotype under a phase-contrast microscope (a, b). Flow cytometric analyses indicated that the 
cultured WJMSCs significantly express mesenchymal stem cell marker CD44 (c). These cells were almost negative for hematopoietic marker CD45 (d), 
B. Genetic engineering of WJMSCs by anti-ADK miR-sh7. WJMSCs observed under phase-contrast microscope (b). Stable transduced WJMSCs with anti-
ADK miR-sh7 under fluorescent microscope (a). Puromycin- selected WJMSCs transduced with anti-ADK miR-shSC (1.5 μg/ml) (c), and C. Western blot 
analysis confirmed ADK knockdown in WJMSCs. Western blot analysis was performed on cell lysates from WJMSCs, WJMSC- miR-sh7, WJMSC-miR-shSC, 
and HepG2. ADK staining (top) and β-actin staining (bottom). WJMSC- miR-sh7 showed the most marked reduction of ADK expression at protein level.
Discussion
In adult brain, ADK is a key enzyme in astrocytes 
that regulates adenosine level by converting 
adenosine to 5′-adenosine monophosphate (AMP) 
and subsequently generates ATP (17). When trauma 
or epilepsy happens, adenosine, as a modulator of 
inflammation increases and induces proliferation of 
astrocytes via A2ARs, leading to astrocyte activation 
and ADK overexpression. ADK expression results in 
adenosine decline. In an acute injury or intractable 
epilepsy, proliferation of astrocytes (i.e. astrogliosis), 
is the pathological hallmark of the disease and at the 
molecular level, adenosine deficiency is the consequence 
of ADK overexpression induced by over-activation of 
astrocytes (18). So, ADK down-regulation and increasing 
adenosine release are among the strategies used for the 
treatment of some neurological disorders like epilepsy. 
Although inhibition of ADK with chemical and small 
molecule drugs can suppress seizures but systemic long-
term use of this therapeutic approach may increase the 
risk of side effects like brain hemorrhage (19). Post-
transcriptional gene silencing is a molecular tool that 
has opened new windows in recent years. Knockdown 
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can increase adenosine and results in suppressing seizures 
via a paracrine effect (20). Epilepsy is a chronic disease 
so permanent release of adenosine is needed. In this 
therapeutic approach, the combination of cell therapy 
with gene therapy is the key to the riddle.
Cell therapy provides long-lasting focal delivery of 
antiepileptic molecules like adenosine and prevents 
systemic pharmacological side effects. Cell therapy also 
has the potential to restore cells that are destroyed by 
neurological conditions, especially in refractory epilepsy. 
In cell therapy approaches, safer and more controllable 
gene delivery of inhibitory neurotransmitters or other 
therapeutic compounds is possible. Chemical mutations 
for engineering cells to release therapeutic agents like 
adenosine, were induced in 2001. In that study, fibroblasts 
that release adenosine were generated by induction a 
deficiency in ADK and adenosine deaminase (ADA) gene 
(21). Transplantation of these cells implicated nearly 
complete protection against seizures up to 24 days but 
lost their antiepileptic effects after that as the viability of 
grafting fibroblast cells decreased. Stem cells are more 
attractive sources to be used for solving this problem. 
Stem cells in addition to having higher viability, can 
be differentiated into multi-lineage cells such as neuro-
progenitor cells to integrate into damaged neural networks 
that are created during epilepsy or other neurological 
disorders, they can slow seizure development and they 
have anti-epileptogenesis effects by releasing inhibitory 
substances.  
Different sources of stem cells (e.g. adult stem cells, 
fetal stem cells, embryonic stem cells and iPS cells) 
have been used to evaluate treatment of animal model of 
epilepsy (22-25). Therapeutic application of ADK gene 
knockout in mouse embryonic stem cells and ADK gene 
knockdown in bone marrow mesenchymal stem cells 
have been investigated by Li et al. (26). These studies 
implicated reduction of seizures in a mouse model after 
transplantation of hMSCs and the results were promising 
to be used for treatment of epilepsy. However, ethical 
concerns about embryonic stem cells and technical issues 
related to bone marrow mesenchymal stem cells, have 
made WJMSCs as an attractive source for cell therapy 
and gene delivery systems. 
WJMSCs could be obtained from the human umbilical 
cord that is normally discarded after the birth. These cells 
are actually a by-product of childbirth. WJMSCs have the 
potential to differentiate into ectodermal and mesodermal 
derived cells (27, 28).  In addition to the easy access to 
WJMSCs and their potential of differentiation, these 
cells have anti-inflammatory and immunomodulatory 
properties. Some studies have shown that xenograft 
transplantation of WJMSCs are not rejected in an animal 
model of human disease without immune-suppression 
(29). Studies suggested that production of cytokines 
and growth factors by WJMSCs, results in their anti-
inflammatory and neuro-protective activities (30). In 
the present study, we improved therapeutic benefit of 
WJMSCs by knocking down ADK gene and producing 
adenosine releasing WJMSCs to suppress seizures in 
families with status epilepticus and we stored these 
cells for possible future applications. WJMSCs are an 
attractive alternative source for cell-based gene therapy 
as they are i. Easily accessible stem cell sources without 
ethical and technical concerns, ii. Accessible in unlimited 
numbers and, iii. Amenable to genetic modification, and 
iv.  They possess therapeutic potential. Based on these 
considerations, we selected these cells for engineering 
with lentiviral anti-ADK miR-shRNA expressing systems.
miRNA-mediated downregulation of ADK was 
previously reported by Li et al. (26). They used five 
anti-ADK miRNA expression cassettes and showed 
downregulation (up to 85%) of ADK in human MSCs 
(hMSCs). In the present study, we considered human 
miR 30 for designing stem-loop and flanking sequences 
of anti-ADK miR-shRNAs to increase the efficiency of 
RNAi-based gene therapy. We used eight anti-ADK miR-
shRNAs that target ADK at different sense and antisense 
sequences but at common stem-loop and flanking 
sequences.
By developing this system, we succeeded to 
diminish ADK expression up to 95% in astrocytoma cell 
line and in WJMSCs. ADK mRNA has 4 variants (isoform 
a, b, c and d). These eight anti-ADK miR-shRNAs can 
target all transcript variants of ADK. Antisense of sh6 and 
sh8 target ADK mRNA at 3´ outside of coding sequence 
(CDs) while other shRNAs (sh1, sh2, sh3, sh4, sh5 and 
sh7) target ADK mRNA at 3´ including CDs. Using 
human miR30 for designing shRNAs caused 60-95% 
knockdown of ADK   (except for sh8 which resulted in 
23% downregulation). Anti-ADK miR-sh4 and Anti-
ADK miR-sh7 were the most efficient cassettes with up 
to 86 and 95% downregulation of ADK,  respectively. 
These results show that the usage of miR-based shRNAs 
is an efficient method in knocking down ADK.  Based on 
these results, in our future research, we work on using 
engineered WJMSC for the survey of the therapeutic 
potential of ADK down-regulation and adenosine delivery 
in an animal model.
Conclusion
Results show that lentiviral system expressing anti-
ADK miR-shRNAs that was used in this study is a 
promising tool for ADK knockdown in all transcript 
variants. Manipulated WJMSCs by Adeno, AAV, non-
integrated lentiviral, CRISPR/Cas9 and RNA transfer 
instead of lentivirus, might be a suitable source in cell-
based and ex vivo gene therapy of epilepsy and could be 
evaluated for ADK knockdown, in vivo.
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